NOCIRA® Expands Patent Portfolio for Personalized Migraine Treatments
Nocira LLC, an Arizona-based medical device company, has recently been granted patents in the United States, Europe, and Japan for its pioneering inventions that personalize migraine treatment based on the symptoms of each migraine. This development adds to Nocira's portfolio of fourteen patents in the U.S. and forty-seven worldwide, focusing on new approaches for treating migraine attacks and other neurological disorders.
Dr. David George, Chief Science Officer and one of the original Inventors and Founders of Nocira, explains the significance of personalizing migraine treatment. He notes that migraine headaches can vary in pain locations and intensities between attacks, suggesting that the underlying neurologic mechanisms causing the pain might also vary. This variability indicates that treatments should also vary to effectively relieve pain.
Nocira's approach to personalized migraine treatment involves a non-invasive neuromodulation platform called "Automated Variable Pulse Insufflation™" (AVPI™). This platform uses gentle air pressure changes through earbuds to stimulate physiological pressure sensors in the ears, connected to areas of the brain that regulate pain and other migraine symptoms. The treatment is personalized and adapted in real-time based on the patient's response, resulting in rapid and complete pain relief within about 20 minutes for most migraines treated in clinical trials.
The effectiveness of Nocira's AVPI approach, demonstrated in multiple clinical trials, suggests it may be more effective and faster-acting than current migraine drugs and devices. These trials have also shown no significant side effects, adverse events, or contraindications, making the Nocira device a user-friendly and pleasant experience for patients.
Nocira is currently raising funds to support FDA approval and CE Mark application, aiming to commercialize the AVPI platform to help millions of migraine patients. The company also plans to continue investing in clinical trials and development to expand the AVPI platform for other medical conditions.
Nocira's commitment to developing safe and rapidly effective, drug-free treatments for neurological disorders has been recognized with awards such as "Emerging Neurology Device Company of the Year" and "Top 10 Neuromodulation Solution Provider" by MedTech Outlook®.